

1 **High frequency of Exon 20 S768I *EGFR* mutation detected**
2 **in malignant pleural effusions: a poor prognosticator of**
3 **NSCLC?**

4 George D'Souza^{1,2*}, Chirag Dhar^{1,2,3*}, Vishal Kyalanoor³, Lokendra Yadav³, Mugdha Sharmra^{1,4},
5 Mohammad Nawaz S², Sweta Srivastava³

6
7 ¹St. John's Research Institute, Bangalore, India

8
9 ²Department of Pulmonary Medicine, St. John's Medical College and Hospital, Bangalore, India

10
11 ³School of Medicine, University of California, San Diego, La Jolla, U.S.A.

12
13 ⁴Department of Transfusion Medicine and Immunohaematology, St. John's Medical
14 College and Hospital, Bangalore, India

15
16 ⁵Department of General Medicine, St. John's Medical College and Hospital, Bangalore, India

17
18 * Equal contribution of authors

19
20 Corresponding authors: Dr. Sweta Srivastava- sweta.s@stjohns.in, Dr. George D'Souza-
21 george.dsouza@stjohns.in and Dr. Chirag Dhar- cdhar@ucsd.edu/
22 chirag@worldviewofmedicine.org

23 **Abstract**

24 Lung cancer is the cause of a fourth of all cancer-related deaths. About a third of all lung
25 adenocarcinoma tumours harbour mutations on exons 18, 19, 20 and 21 of the epidermal growth
26 factor receptor (*EGFR*) gene. Detection of these mutations allows for targeted therapies in the
27 form of *EGFR* Tyrosine kinase inhibitors. In our study, we utilized malignant pleural effusions
28 (MPEs) as “liquid biopsies” to detect *EGFR* mutations when tissue biopsies were unavailable.
29 We showed that a direct sequencing approach was likely to miss SNVs in MPEs. We then
30 optimized an *EGFR* mutant-specific quantitative polymerase chain reaction-based assay and
31 piloted it on n=10 pleural effusion samples (1 non-malignant pleural effusion as a negative
32 control). 5/9 (55.55%) samples harboured *EGFR* mutations with 2/9 (22.22%) being exon 19
33 deletions and 3/9 (33.33%) had the S768I exon 20 mutation. The frequency of the S768I SNV in
34 our study was significantly higher than that observed in other studies (~0.3%). Utilizing publicly
35 available cBioPortal data, we report that patients with the S768I SNV had a shorter median
36 survival time, progression-free survival time and lower tumor mutation count compared to
37 patients with other *EGFR* mutations. These data suggest that this point mutation predicts poor
38 prognosis as a result of aggressive disease, though studies in larger cohorts are necessary to
39 confirm these findings. The high frequency of S768I mutations seen in our study also suggests
40 that cancer cells harbouring these mutations may be superior in their ability to migrate, home or
41 reside in pleural fluid.

42

43 **Introduction**

44 Lung cancer is a major contributor to death due to cancer. Amongst the various types of
45 lung cancer, non-small cell lung cancer (NSCLC) accounts for approximately 80% of all

46 cases(1). A significant rise has been seen in the time trends of lung cancer in the Indian cities of
47 Delhi, Chennai and Bangalore. Lung cancer is the cause of 6.9 percent of all new cancer cases
48 and 9.3 percent of all cancer related deaths in both men and women in India (2). Mutations seen
49 on Exons 18, 19, 20 and 21 of the Epidermal growth factor receptor (*EGFR*) gene are frequently
50 observed in these cases and have been shown to be present in nearly a third of all lung
51 adenocarcinoma cases (3)(4)(5). *EGFR* is a family member of receptor tyrosine kinases that play
52 a central role in cellular signalling promoting cell growth and proliferation. Some mutations in
53 this protein strongly predict the efficacy of *EGFR* tyrosine kinase inhibitors used in the treatment
54 of these cases. There are reportedly more than 32 different mutations that have been detected in
55 this gene distributed across exons 18, 19, 20, and 21 (6)(7). More than 20 different in-frame
56 deletions on exon 19 have been reported accounting for nearly half of the cases of *EGFR* mutant
57 lung adenocarcinoma. Importantly, tumours harbouring these deletions are found to be sensitive
58 to *EGFR* TKIs such as erlotinib and gefitinib (8). This targeted therapy has been found to
59 increase clinical outcomes in these patients (9). Response rates of more than 70 percent have
60 been observed in patients on *EGFR* targeted therapy (10). Patients with *EGFR* mutant positive
61 advanced NSCLC treated with Erlotinib, an *EGFR* Tyrosine kinase inhibitor (TKI) have shown
62 better response rates and Progression-free survival (PFS) as compared to those on first line
63 chemotherapeutic agents (11)(12)(13)(14).

64 Diagnostic tests for the detection of these *EGFR* mutations are now part of the routine
65 management of lung adenocarcinoma(15). In spite of the invasiveness and morbidity associated
66 with lung biopsies(16), the primary tumour is preferred for detection of mutations(17). Most
67 often, an amplification-refractory mutation system (ARMS) is used for the detection of these
68 mutations from the biopsy. The utility of malignant pleural effusion (MPE) in the detection of

69 EGFR mutations has been well established over the years in the field of lung cancer
 70 diagnosis(18). In this study, we optimized a method to detect EGFR mutations in MPEs at our
 71 tertiary care centre. Notably, the single nucleotide variant (SNV) S768I was found in 3 out of the
 72 9 pleural effusions (33.33%). We then analysed the prevalence and clinical features of patients
 73 harboring this SNV by utilizing cBioPortal (www.cbioportal.org).

74

75 Results

76 Dilutions of mutant in wildtype EGFR DNA predict poor sensitivity of direct sequencing- 77 based detection of SNVs in MPEs.

78 First, a direct sequencing-based approach was optimized to detect EGFR mutations from
 79 MPEs. A common exon 19 deletion was detected using this method (figure 1 a and b). We then
 80 asked if this method would be suitable to pick up mutant alleles in the backdrop of wildtype
 81 inflammatory cells present in MPEs. To answer this question, we serially diluted DNA with the
 82 exon 19 deletion with wildtype DNA and subjected the mixture to direct sequencing. While
 83 signatures of the large 18bp deletion were visible even in 1:100 dilutions, the results suggested
 84 poor base-call confidence (figure 1 c). This result suggested that the direct sequencing method
 85 was unlikely to pick up SNVs.

86


87 **Figure 1: Poor base-call**
 88 **confidence in diluted DNA**
 89 **samples. a) Common exon 19**
 90 **deletion detected.** Alignment of
 91 MPE sequence with reference



92 sequence shows an 18bp deletion (highlighted in the yellow box). **b) Chromatogram view of**
93 **the same mutation** (highlighted in the yellow box) **c) Alignment of diluted DNA sample.** Poor
94 base-call confidence in sequence of 1:100 dilution of mutant DNA in wildtype DNA (healthy
95 laboratory volunteer).

96 **High frequency of S768I exon 20 mutation detected by mutant-specific quantitative PCR of**
97 **MPE.**

98 Subsequently, an established *EGFR* mutation real-time PCR kit was used to identify
99 *EGFR* mutations in malignant pleural effusions. While this kit is optimized to detect mutations in
100 genomic DNA obtained from primary tumors, we attempted to utilize MPEs instead. We
101 demonstrated for the first time that this kit could detect *EGFR* mutations from MPEs. Our results
102 showed that 5/9 (55.55%) of pleural effusions probed had *EGFR* mutations. Of these, 2/9
103 (22.22%) were the exon 19 deletion E746_S750del18 and 3/9 (33.33%) were the exon 20 S768I
104 mutations (Figure 2 a and b). The amplification plots and ΔC_t values are provided in
105 supplementary figures 1-7 and supplementary tables 1 and 2. The occurrence of this SNV and
106 clinical features of these patients was then studied using publicly available data on cBioPortal.
107 This SNV has been detected only 17 times in the nearly 5836 (0.3%) non-small cell lung cancer
108 samples surveyed for *EGFR* mutations (Figure 2 c). These detections include duplicates and the
109 frequency at the patient level is 0.18% (10/5490 patients). This SNV is mapped onto the
110 tyrosine-kinase domain of *EGFR* and is a known cancer hotspot (statistically significantly
111 recurrent mutations identified from large scale cancer genomic studies) (Figure 2 d). Patients
112 with this mutation are suitable candidates for the FDA-approved targeted therapy Afatanib.




113
 114 **Figure 2: High frequency of S768I detected from MPEs. a) Table depicting gender,**
 115 **mutation detected and exon of occurrence. M= Male, F= Female, WT= wildtype *EGFR*, S5**
 116 **was a non-malignant pleural fluid sample that served as an internal assay negative control b)**
 117 **Doughnut chart representing the frequency of various mutations detected in this study.**
 118 **Percentages are embedded in the slices and number of cases observed are indicated in**
 119 **parenthesis beneath the genotype. c) Frequency of S768I in other studies. cBioPortal data**
 120 **shows that this SNV has been detected only 17 times at a frequency of 0.4%. d) Mapping of**
 121 **S768I. S768I maps to the tyrosine kinase domain of *EGFR* and is a known cancer hotspot.**


122
 123
 124
 125

126 **Patients having the S768I mutation have a shorter median survival time and a shorter**
 127 **progression-free survival time compared to patients having other *EGFR* mutations.**

128 From publicly available cBioPortal data, patients with the S768I mutation have a median
 129 survival of 6.20 months compared to 38.40 months patients with other *EGFR* mutations (figure 3
 130 a, b and c). Additionally, patients with the SNV had a shorter progression-free survival times
 131 (8.55 months for patients with S768I vs 44.02 months for patients with other *EGFR* mutations,
 132 figures 4 a, b and c). These survival statistics (limited by number of patients) suggest that
 133 patients with this SNV present with an advanced form of NSCLC.



134 **Figure 3: Patients having the S768I mutation have a shorter median survival time**
 135 **compared to patients having other *EGFR* mutations. a) Kaplan-Meier (KM) survival curve**
 136 **b) KM curve for first 60 months inset c) Median survival in months suggest shorter median**
 137 **survival in patients with S768I. Unaltered refers to NSCLC patients without *EGFR* mutations,**
 138 **EGFR to patients with *EGFR* mutations except S768I and S768I refers to patients with this SNV.**



140
141 **Figure 4: Patients having the S768I mutation have a shorter progression-free survival time**

142 **compared to patients having other EGFR mutations. a) Kaplan-Meier (KM) survival curve**

143 **b) KM curve for first 60 months inset c) Median survival in months suggest shorter median**

144 **time to relapse in patients with S768I. Unaltered refers to NSCLC patients without EGFR**

145 **mutations, EGFR to patients with EGFR mutations except S768I and S768I refers to patients**

146 **with this SNV.**

147

148 **Presence of the S768I SNV was not associated with a significant difference in stage at**

149 **diagnosis, lymph node involvement, size of tumor and metastasis.**


150 Given the poorer survival in the S768I group, we compared the stage at diagnosis, lymph nodal

151 involvement, size of tumor and metastasis between the groups. There was no difference in the

152 stage at diagnosis between patients with or without the S768I mutation (figure 5 a). There also

153 was no discernible difference in lymph nodal involvement (figure 5 b) or tumor size (figure 5 c)

154 between the two groups possibly due to the small sample size in the S768I group. We then
 155 queried the number metastasis samples obtained from these patients as a proxy for frequency of
 156 metastasis. Again, there was no difference in the frequency between the groups (figure 5 d). It is
 157 likely that a larger meta-analysis of this SNV may reveal discernible differences in these factors
 158 but in a limited number of cases with available data this was not the case.




159
 160 **Figure 5: No observable differences in stage at diagnosis, lymph nodal involvement, tumor**
 161 **stage code or metastasis in tumors with S768I. Differences between groups by a) Stage at**
 162 **diagnosis b) Lymph nodal involvement c) Tumor stage code and d) metastatic lesions**
 163 **sampled as a proxy for metastatic frequency.** Unaltered refers to NSCLC patients without
 164 *EGFR* mutations, EGFR to patients with *EGFR* mutations except S768I and S768I refers to
 165 patients with this SNV.

166
 167

168 **Tumors with the S768I SNV have a lower mutation burden but co-occur with mutations on**
 169 **other genes.**

170 We then asked if patients with the S768I patients had a lower mutation count compared
 171 to patients with other *EGFR* mutations. Indeed, the number of mutations was lower in the S768I
 172 group (figure 6 a) suggesting a more deleterious effect of this SNV. These data when taken
 173 together with the survival data point towards a likely pathogenic role of S768I in advanced
 174 NSCLC. Further analysis revealed association of the S768I SNV with other mutations. This SNV
 175 was as likely to co-occur with TP53 mutations as tumors with no EGFR mutations or ones with
 176 other EGFR mutations. Yet, S768I co-occurred with mutations on other genes such as MUC17,
 177 BMPR2, DOCK3, TPTE, ATRX and FSHR (figure 6 b, c and d). The clinical significance or
 178 mechanistic importance of these co-occurring mutations is unknown.



179
 180 **Figure 6: Lower tumor mutation in patients with S768I and co-occurrence with other**
 181 **mutations. a) Mutation load in tumors with S768I.** The overall mutation load in tumors with
 182 the S768I SNV is lower than in tumors with other EGFR mutations or NSCLC samples with

183 other mutations. **b) Graphical representation of genes mutated more frequently in tumors**
184 **positive for S768I but not in tumors with other EGFR mutations.** **c) Dot plot depicting**
185 **frequency of co-occurring mutations in S768I tumors.** Blue dots represent genes with a
186 statistically significant p-value. **d) Bar graphs of 25 most frequently detected mutations**
187 **(apart from EGFR).** TP53 mutation frequency is nearly the same but mutations in genes such as
188 FLG, MUC17, BMP2, DOCK3, TPTE, ATRX and FSHR mutations appear more frequently in
189 conjunction with the S768I mutation. Asterisk (*) genes represent those with statically
190 significant differences. A list of all 175 genes with statistically significant co-occurrence with
191 S768I are listed in the supplementary information.

192

193 **Discussion**

194 In this study, we showed that a direct sequencing approach may miss *EGFR* SNVs in
195 MPEs and therefore utilized a Taqman-based mutant-specific quantitative PCR assay. We
196 optimized this assay and detected both large deletions and SNVs in *EGFR*. Notably, a high
197 frequency of the S768I mutation occurring in the absence of other *EGFR* mutations was seen.
198 We then compared this frequency to publicly available data on cBioPortal[®] and observed a
199 significant difference in frequency (33.33% in our study vs 0.4% in reported literature). To
200 further understand the role of this SNV, a cBioPortal[®] search and comparison strategy was
201 devised to compare the clinical features of patients with the SNV, patients with other *EGFR*
202 mutations and patients with no mutations in *EGFR*. Patients with the S768I had an 84% reduction
203 in estimated median survival time (and progression-free survival time) compared to those with
204 other *EGFR* mutations. Tumors bearing the S768I mutation also had a lower mutational than the
205 other *EGFR* mutations group. These data when taken together suggests that patients with the

206 S768I mutation have poorer clinical outcomes and this mutation is likely to promote an
207 aggressive tumor phenotype.

208

209 Very little is known about the implications of having the S768I mutation in the absence
210 of other *EGFR* mutations. OncoKB suggests the use of afatinib as the FDA-approved therapy for
211 patients with this SNV. One other study shown that S768I conferred reduced sensitivity to
212 gefitinib *in vitro* as compared to other mutations (19)(20). A study by Leventakos and group
213 reported that the S768I is rare and is usually found in combination with sensitizing mutations
214 and they have concluded that the predictive and prognostic role of this mutation is yet to be fully
215 explored (21). In our study we have found that 33.3% of the samples exhibited this mutation in
216 isolation, with an absence of any other mutation. It did not escape our attention that all reports of
217 this SNV in studies discussed here occur in the presence of other EGFR mutations (such as at the
218 G719 or T790 position). Some of the reasons for this mutation being detected in the absence of
219 other *EGFR* mutations in our study are discussed here. Most studies utilize the primary tissue
220 and a sub-population with this isolated mutation may appear later in the pathogenesis of the
221 disease. One may also simply come to the conclusion that our cohort has a larger number of
222 patients with this mutation, but we think otherwise. We hypothesize that S768I is a secondary
223 mutation that develops later in the course of the disease and cells harbouring this mutation are
224 able to migrate to, home in or reside within the pleural cavity more easily than cells without this
225 mutation. One could further this speculation that cells having this mutation have a greater
226 metastatic potential (figure 7) though further studies will be needed to prove these hypotheses.
227 Additionally, *in vitro* and *in vivo* studies will determine if this mutation is likely to respond to
228 EGFR TKIs such as afatinib.

229




Figure 7: Hypothesized role of the S768I mutation in the pathogenesis of metastasis in lung cancer (Elements of images sourced from <http://smart.servier.com/>).

238

239 The prevalence of somatic mutations in the *EGFR* gene is high (~ 33%) in lung
240 adenocarcinomas(22)(23). The detection of any *EGFR* mutation and the resultant treatment with
241 targeted therapy with EGFR TKIs (Tyrosine Kinase Inhibitors) aid in sensitizing these tumours.
242 *EGFR* mutation testing on tissue biopsies is the gold standard for diagnosis. However, biopsy
243 procedures may result in uncontrolled bleeding and morbidity(24). Utility of pleural effusion
244 fluid for mutation testing along with other secondary specimens (pericardial effusion, fine needle
245 aspirates, CSF, cfDNA, etc) have been used as alternate strategies for reliable testing (25). In our
246 study we first used PCR coupled to direct sequencing to detect mutation in pleural effusion
247 derived malignant cells. We were able to detect a common 18bp deletion mutation using this
248 method. One of the biggest drawbacks of direct sequencing versus allele specific detection lies in
249 its limit of detection. Pleural fluid consists of a heterogeneous pool of stromal and inflammatory
250 cells apart from the metastatic cells. Since the non-tumor cells harbour wildtype genomic
251 sequence, the signal to noise ratio in electropherogram is lower for mutated sequence. The

252 mutation sequence identification may be compromised in the event of suboptimal malignant cells
253 numbers. We showed that at dilution of 1:100 of a mutated DNA with wildtype genomic DNA
254 signatures of the mutation are visible but the wildtype sequence bases provide conflicting results
255 in certain positions of the gene. These inadequate results are more likely to be seen in single base
256 pair mutations. We then utilized an *EGFR* mutation detection kit. This diagnostic kit is designed
257 to test for *EGFR* mutation on FFPE sections but we were able to optimize its use on MPEs. To
258 the best of our knowledge, this is the first report of MPE *EGFR* mutation testing in India
259 utilizing the Taqman technology platform. Jong Sik Lee and colleagues have used PNA
260 clamping technology to detect EGFR mutations in the supernatant derived from the pleural
261 effusion where in the objective was to detect mutations using cell free DNA (26). Jie Lin et al
262 have shown that EGFR mutations can be detected in the supernatant, cell pellets of the pleural
263 effusion using High Resolution Melting (HRM) analysis and Sanger sequencing (27). When
264 implemented on a small pilot scale study (n=9), we were successful in detecting EGFR mutations
265 in 5/9 (55%) subjects. The mutations that were detected in these samples were either S768I or
266 E746_S750del.

267
268 The need to develop minimally invasive diagnostic tests in the management of cancers is
269 gaining momentum. However, our study is limited in its impact as it evaluates only 11 patients
270 and further study needs to be undertaken to evaluate and validate this method in a larger cohort.
271 Additionally, the detection of circulating tumour DNA should also be explored as an alternative
272 to repeated biopsies is one of the techniques being studied (28). This detection is being done
273 using highly sensitive techniques such as droplet digital polymerase chain reaction. Resources

274 must be directed towards the development of such minimally/non-invasive techniques, especially
275 if these are inexpensive as well.

276

277 **Ethics**

278 Ethical clearance was obtained from the Institutional Ethics Committee of St. John's
279 National Academy of Health as per IERB guidelines (Study No. 1/2016). Appropriate consents
280 for carrying out experimental genetic tests were obtained.

281

282 **Methods**

283

284 **Pleural fluid processing and DNA isolation**

285 Pleural fluid was tapped from patients with malignant pleural effusions and centrifuged at
286 3500 rpm for 5 mins at 4°C to collect the cell pellet. The cell pellets were stored in -80°C until
287 further processing. The DNA was extracted from the samples using the QIAamp DNA Mini Kit
288 (Qiagen) as per the manufacturer's instructions. Samples were analyzed for their quality using
289 BioSpec Nano UV-VIS Spectrophotometer (Shimadzu Corp.) and electrophoresed on an agarose
290 gel to ascertain integrity.

291

292 **Direct sequencing**

293 Appropriate primers for exons 18, 19, 20 and 21 of the EGFR gene were designed and
294 obtained based on the reference sequence available on NCBI (Supplementary table 2). Genomic
295 DNA obtained was subjected to a gradient PCR to optimize the annealing temperature and was

296 visualized on a 1.2% agarose gel (Supplementary figure 8). The PCR products were subjected to
297 direct sequencing.

298

299 **Real-time PCR based detection of EGFR mutations**

300 DNA samples were subjected to an assay to detect 10 *EGFR* mutations in a 96-well
301 Real Time PCR format using the TRUPCR® EGFR Kit (3B BlackBio Biotech India Ltd.) as per
302 the manufacturer's instructions. Real-time PCR data analysis and identification of EGFR mutant
303 samples was done. To the best of our knowledge, this is the first time this kit is being used to
304 detect mutations from MPEs.

305

306 **cBioPortal search strategy**

307 A search strategy was used to access publicly available cancer genomic/clinical data on
308 cBioPortal(29)(30) utilizing multiple studies(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)
309 with the gene alias “EGFR: MUT = S768I”, “EGFR” and to access all NSCLC studies. Venn-
310 diagram based sorting was utilized to isolate cases with the S768I mutation and those with other
311 *EGFR* mutations. “Unaltered” refers to patients with mutations other than EGFR, “EGFR” refers
312 to patients with *EGFR* mutations other than S768I and “S768I” refers to patients with the S768I
313 *EGFR* mutation. OncoKB(43) was used to identify any FDA-approved drug for this mutation.

314

315 **Acknowledgements**

316 This work is supported by a grant from the Advanced Research Wing of the Rajiv Gandhi
317 University of Health Sciences, Bangalore. C.D. was awarded a C.R.E.S.T MAS scholarship by
318 CTRI at the School of Medicine, University of California, San Diego. We thank Prof. Sudhir

319 Krishna, Ms. Pranatharathi Annapurna and the sequencing division of NCBS, Bangalore for their
320 support. Some of these data were presented at the National Lung Cancer Conference 2016 in
321 Bhubaneswar and at the American Society for Cellular Biology-European Molecular Biology
322 Organization joint conference 2018 at San Diego(44)(45)(46) . A special mention to Dr. Paul
323 Kalanithi for his battle against EGFR mutant lung cancer. His memoir When Breath becomes Air
324 is humbling and yet, inspiring.

325

326 **Conflict of Interest**

327 The authors declare no conflict of interest.

328

329 **Author contributions**

330 G.D.S and C.D contributed equally this work which was conceived, planned, supervised
331 and interpreted by G.D.S, C.D and S.S. Funding acquisition was by G.D.S. Experimental assays
332 were performed and interpreted by C.D., V.K., L.Y. and M.S. Clinical sample acquisition was by
333 C.D., M.N.S. and G.D.S. C.D. performed cBioPortal/bioinformatic analysis. Manuscript was
334 written and edited by C.D. and V.K. S.S. edited the manuscript. All authors approved the final
335 manuscript.

336

337 **References**

- 338 1. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid
339 of malignant pleural effusion in non-small cell lung cancer.
- 340 2. Malik PS, Raina V. Lung cancer: prevalent trends & emerging concepts. Indian J Med Res.
341 2015 Jan;141(1):5–7.
- 342 3. Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, et al. Clinical and
343 epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian
344 patients with adenocarcinoma of the lung. OncoTargets Ther. 2015;8:117–23.

- 345 4. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic
346 mutations affect key pathways in lung adenocarcinoma. *Nature*. 2008 Oct
347 23;455(7216):1069–75.
- 348 5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene
349 mutations are common in lung cancers from “never smokers” and are associated with
350 sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A*. 2004 Sep
351 7;101(36):13306–11.
- 352 6. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations
353 in lung cancer. *Nat Rev Cancer*. 2007 Mar;7(3):169–81.
- 354 7. Cosmic. COSMIC - Catalogue of Somatic Mutations in Cancer [Internet]. [cited 2020 Mar
355 6]. Available from: <https://cancer.sanger.ac.uk/cosmic>
- 356 8. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A,
357 et al. Molecular pathology of lung cancer: key to personalized medicine. *Mod Pathol Off J*
358 *U S Can Acad Pathol Inc*. 2012 Mar;25(3):347–69.
- 359 9. Rocha-Lima CM, Raez LE. Erlotinib (tarceva) for the treatment of non-small-cell lung
360 cancer and pancreatic cancer. *P T Peer-Rev J Formul Manag*. 2009 Oct;34(10):554–64.
- 361 10. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or
362 carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009 Sep
363 3;361(10):947–57.
- 364 11. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy
365 as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell
366 lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3
367 study. *Lancet Oncol*. 2011 Aug;12(8):735–42.
- 368 12. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib
369 versus standard chemotherapy as first-line treatment for European patients with advanced
370 EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label,
371 randomised phase 3 trial. *Lancet Oncol*. 2012 Mar;13(3):239–46.
- 372 13. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line
373 gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR
374 mutations. *J Clin Oncol Off J Am Soc Clin Oncol*. 2008 May 20;26(15):2442–9.
- 375 14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and
376 biological features associated with epidermal growth factor receptor gene mutations in lung
377 cancers. *J Natl Cancer Inst*. 2005 Mar 2;97(5):339–46.
- 378 15. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small-cell
379 lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and
380 follow-up. *Ann Oncol Off J Eur Soc Med Oncol*. 2012 Oct;23 Suppl 7:vii56-64.

- 381 16. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications
382 after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge
383 records. *Ann Intern Med*. 2011 Aug 2;155(3):137–44.
- 384 17. Pirker R, Herth FJF, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR
385 mutation testing in non-small cell lung cancer: results from a European workshop. *J Thorac
386 Oncol Off Publ Int Assoc Study Lung Cancer*. 2010 Oct;5(10):1706–13.
- 387 18. Liu D, Lu Y, Hu Z, Wu N, Nie X, Xia Y, et al. Malignant Pleural Effusion Supernatants
388 Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients
389 with Advanced Lung Adenocarcinoma. *PLoS ONE* [Internet]. 2014 Feb 28 [cited 2020 Apr
390 3];9(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938554/>
- 391 19. Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth
392 factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
393 *Clin Cancer Res Off J Am Assoc Cancer Res*. 2009 Jan 15;15(2):460–7.
- 394 20. Chen Y-R, Fu Y-N, Lin C-H, Yang S-T, Hu S-F, Chen Y-T, et al. Distinctive activation
395 patterns in constitutively active and gefitinib-sensitive EGFR mutants. *Oncogene*. 2006 Feb
396 23;25(8):1205–15.
- 397 21. Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS. S768I Mutation
398 in EGFR in Patients with Lung Cancer. *J Thorac Oncol Off Publ Int Assoc Study Lung
399 Cancer*. 2016;11(10):1798–801.
- 400 22. Zhang Y-L, Yuan J-Q, Wang K-F, Fu X-H, Han X-R, Threapleton D, et al. The prevalence
401 of EGFR mutation in patients with non-small cell lung cancer: a systematic review and
402 meta-analysis. *Oncotarget*. 2016 Oct 12;7(48):78985–93.
- 403 23. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, et al. EGFR
404 mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of
405 adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. *Lung Cancer
406 Amst Neth*. 2017;113:37–44.
- 407 24. Lim M, Kim C-J, Sunkara V, Kim M-H, Cho Y-K. Liquid Biopsy in Lung Cancer: Clinical
408 Applications of Circulating Biomarkers (CTCs and ctDNA). *Micromachines*. 2018 Feb
409 28;9(3).
- 410 25. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing
411 in lung cancer: a review of available methods and their use for analysis of tumour tissue and
412 cytology samples. *J Clin Pathol*. 2013 Feb;66(2):79–89.
- 413 26. Lee JS, Hur JY, Kim IA, Kim HJ, Choi CM, Lee JC, et al. Liquid biopsy using the
414 supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma
415 patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
416 *BMC Cancer*. 2018 Dec 10;18(1):1236.

- 417 27. Lin J, Gu Y, Du R, Deng M, Lu Y, Ding Y. Detection of EGFR mutation in supernatant,
418 cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by
419 high resolution melting analysis and sequencing. *Int J Clin Exp Pathol*. 2014;7(12):8813–
420 22.
- 421 28. Suraj S, Dhar C, Srivastava S. Circulating nucleic acids: An analysis of their occurrence in
422 malignancies. *Biomed Rep*. 2017 Jan;6(1):8–14.
- 423 29. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer
424 genomics portal: an open platform for exploring multidimensional cancer genomics data.
425 *Cancer Discov*. 2012 May;2(5):401–4.
- 426 30. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis
427 of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013
428 Apr 2;6(269):pl1.
- 429 31. Thoracic PDX (MSK, provisional) [Internet]. Available from: cBioPortal.org
- 430 32. Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, et al.
431 Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.
432 *Cancer Cell*. 2018 08;33(1):125–136.e3.
- 433 33. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular
434 Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed
435 Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled
436 With Targeted Next-Generation Sequencing. *J Clin Oncol Off J Am Soc Clin Oncol*. 2018
437 01;36(7):633–41.
- 438 34. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al.
439 Tracking the Evolution of Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017
440 01;376(22):2109–21.
- 441 35. Gobbin E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, et al. Molecular profiling in
442 Italian patients with advanced non-small-cell lung cancer: An observational prospective
443 study. *Lung Cancer Amst Neth*. 2017;111:30–7.
- 444 36. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer
445 immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small
446 cell lung cancer. *Science*. 2015 Apr 3;348(6230):124–8.
- 447 37. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al. Distinct
448 patterns of somatic genome alterations in lung adenocarcinomas and squamous cell
449 carcinomas. *Nat Genet*. 2016;48(6):607–16.
- 450 38. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping
451 the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell*. 2012 Sep
452 14;150(6):1107–20.

- 453 39. Lung Adenocarcinoma, Lung Squamous Cell Carcinoma (TCGA, Firehose Legacy)
454 [Internet]. Available from: cBioPortal.org
- 455 40. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung
456 adenocarcinoma. *Nature*. 2014 Jul 31;511(7511):543–50.
- 457 41. TCGA PanCancer Atlas [Internet]. TCGA PanCancer Atlas. Available from:
458 <https://www.cell.com/pbassets/consortium/pancanceratlas/pancani3/index.html>
- 459 42. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective
460 Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient
461 Matching to Approved and Emerging Therapies. *Cancer Discov*. 2017;7(6):596–609.
- 462 43. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A
463 Precision Oncology Knowledge Base. *JCO Precis Oncol* [Internet]. 2017 Jul [cited 2020
464 Apr 3];2017. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540/>
- 465 44. Dhar C, Sharma M, Nawaz M, D'Souza G, Srivastava S. Sanger sequencing of metastatic
466 pleural effusion: An inexpensive, minimally invasive tool for the detection of EGFR
467 mutations in lung adenocarcinoma- Presented at the National Lung Cancer Conference,
468 Bhubaneswar 2016
469 (https://www.researchgate.net/publication/313108485_Sanger_sequencing_of_metastatic_pleural_effusion_An_inexpensive_minimally_invasive_tool_for_the_detection_of_EGFR_mutations_in_lung_adenocarcinoma-Presented_at_the_National_Lung_Cancer_Conference_2016). In.
- 473 45. Dhar C, Sharma M, Nawaz S M et al. Detection of EGFR TKI sensitizing mutations from
474 metastatic pleural fluid secondary to lung adenocarcinoma: a perspective from Southern
475 India. [version 1; not peer reviewed]. *F1000Research* 2018, 7:1943 (poster)
476 (<https://doi.org/10.7490/f1000research.1116357.1>). In.
- 477 46. 2018 ASCB Annual Meeting abstracts. *Mol Biol Cell*. 2018 Dec 15;29(26):3063.
- 478
- 479
- 480
- 481
- 482
- 483
- 484
- 485


486

487

488


489

490 **Supplementary Information**



Supplemental figure 1 shows the amplification curves for different mutations tested in Sample S2

491



Supplemental figure 2 shows the amplification curves for different mutations tested in Sample S4

492

493

494

495


496

497

498

499

500



Supplemental figure 3 shows the amplification curves for different mutations tested in Sample S7

501

502


503

504

505

506

507



Supplemental figure 5 shows the amplification curves for different mutations tested in Sample S9

508

509

510

511

512

513

514

515

516

517


518

519

520

521

522



Supplemental figure 6 shows the amplification curves for different mutations tested in Sample S10

523


524

525

526

527

528
529
530
531
532
533
534



Supplemental figure 7 shows the representative amplification curves for different mutations tested and classified as a Wild Type sample or below LOD

535
536
537

538

Sample No.	ΔC_t								
	G719X	T790M	S768I	EX20INS	C797S	L858R	L861Q	E746_S750DEL	EX19DEL
S1	11.261	12.919	12.393	15.518	13.704	21.527	19.990	14.589	8.697
S2	11.595	12.284	12.148	13.915	12.470	20.835	ND	6.327	9.159
S3	10.997	12.154	11.452	13.572	13.223	19.834	19.788	14.197	8.416
S4	10.981	12.106	12.276	15.961	12.879	18.905	ND	5.597	8.640
S5	12.438	11.107	11.385	14.670	19.424	ND	ND	ND	8.957
S6	11.314	12.079	11.776	17.363	12.901	ND	ND	14.173	8.642

Supplemental table 1 shows the ΔC_t values of Samples S1- S6

539

540

541

542

Sample No.	ΔC_t								
	G719X	T790M	S768I	EX20INS	C797S	L858R	L861Q	E746_S750DEL	EX19DEL
S7	12.212	20.890	4.077	ND	ND	ND	ND	ND	ND
S8	15.164	ND	13.393	ND	ND	ND	ND	ND	ND
S9	13.942	ND	8.558	ND	ND	ND	ND	ND	ND
S10	12.041	ND	6.280	ND	ND	ND	ND	ND	ND

Supplemental table 2 shows the ΔC_t values of Samples S7-S11

543
544
545
546
547

Supplementary table 3

548 List of newly designed primers


Region of Interest	Forward Primer 5' to 3'	Reverse Primer 5' to 3'
Exon 18	GTCCTTCCAAATGAGCTGGCAAG	ACAAAGAGTAAAGTAGATGATGG
Exon 19	TGTCCCTCACCTTCGGGGTGCAT	ACATTTAGGATGTGGAGATGAGCA
Exon 20	CTCAAGATCGCATTTCATGCGTC	GACAGGCACTGATTTGTGCAC
Exon 21	AGTAGTCACTAACGTTCCGCCAG	TCCCAGCAAGTACTGTTCCC

549
550
551

552 **Optimization of a polymerase chain reaction protocol to amplify EGFR exon 18, 19, 20 and**
553 **21 from malignant pleural effusion (MPE).**

554 Initially, we attempted a PCR amplification coupled with a direct sequencing approach to
555 detect EGFR mutations from malignant pleural effusions. Appropriate primers (sequences listed
556 in table 1) were designed and optimized on sample S0. Successful amplification of exons 18-21
557 by PCR on S0 are shown in figure 1. The primers for exon 18 and 21 had 55 °C as the annealing
558 temperature while exon 19 and 20 were best amplified at an annealing temperature of 57.8 °C.

559



560

561 **Supplementary figure 8:** 1.2% Agarose gel imaged under ultra-violet light: 100bp ladder, A:
562 GAPDH, B: Exon 20, lanes C-G: Exon 19 at annealing temperatures of 55 C, 57.8 C, 60.5 C,
563 63.1 C and 65 C lanes H-L: Exon 18 at annealing temperatures of 55 C, 57.8 C, 60.5 C, 63.1 C
564 and 65 C, lanes M-Q: Exon 21 at annealing temperatures of 55 C, 57.8 C, 60.5 C, 63.1 C and 65
565 C Interestingly, two distinct bands are visible for Exon 19 (lanes C-G)

566

567

568

569

570

571

572

573 **List of genes with mutations co-occurring with S768I**

574

Gene	Cytoband	(B) EGFR	(C) S768I	Alteration Overlap	Log Ratio	p-Value	q-Value	Enriched in
PDE1B	12q13.2	5 (0.70%)	6 (35.29%)		-5.66	2.58E-08	1.823E-04	(C) S768I
PNLIP	10q25.3	7 (0.98%)	6 (35.29%)		-5.17	9.33E-08	1.823E-04	(C) S768I
CTNNA1	5q31.2	3 (0.42%)	5 (29.41%)		-6.13	1.94E-07	1.823E-04	(C) S768I
BAG3	10q26.11	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
CDCA7	2q31.1	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
DACH2	Xq21.2	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
KCNA7	19q13.33	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
NKAP	Xq24	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
ODF2	9q34.11	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
PLSCR2	3q24	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
RP2	Xp11.3	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
SLC7A2	8p22	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
TEK3	17p12	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
TOMM70	3q12.2	0 (0.00%)	4 (23.53%)		<-10	2.02E-07	1.823E-04	(C) S768I
TRIM22	11p15.4	4 (0.56%)	5 (29.41%)		-5.71	4.3E-07	3.627E-04	(C) S768I
TLR4	9q33.1	21 (2.94%)	7 (41.18%)		-3.81	8.27E-07	5.99E-04	(C) S768I
C2CD2L	11q23.3	1 (0.14%)	4 (23.53%)		-7.39	9.94E-07	5.99E-04	(C) S768I
GTF2IRD1	7q11.23	1 (0.14%)	4 (23.53%)		-7.39	9.94E-07	5.99E-04	(C) S768I
HIST2H2AB	1q21.2	1 (0.14%)	4 (23.53%)		-7.39	9.94E-07	5.99E-04	(C) S768I
PHC3	3q26.2	1 (0.14%)	4 (23.53%)		-7.39	9.94E-07	5.99E-04	(C) S768I
ZNF304	19q13.43	1 (0.14%)	4 (23.53%)		-7.39	9.94E-07	5.99E-04	(C) S768I
ATRX	Xq21.1	38 (5.65%)	8 (50.00%)		-3.15	1.847E-06	1.062E-03	(C) S768I
CCR6	6q27	2 (0.28%)	4 (23.53%)		-6.39	2.939E-06	1.329E-03	(C) S768I
FCMR	1q32.1	2 (0.28%)	4 (23.53%)		-6.39	2.939E-06	1.329E-03	(C) S768I
SMCR8	17p11.2	2 (0.28%)	4 (23.53%)		-6.39	2.939E-06	1.329E-03	(C) S768I
TNPO2	19p13.13	2 (0.28%)	4 (23.53%)		-6.39	2.939E-06	1.329E-03	(C) S768I
ZBTB10	8q21.13	2 (0.28%)	4 (23.53%)		-6.39	2.939E-06	1.329E-03	(C) S768I
ZNF428	19q13.31	2 (0.28%)	4 (23.53%)		-6.39	2.939E-06	1.329E-03	(C) S768I
FRMPD4	Xp22.2	8 (1.12%)	5 (29.41%)		-4.71	4.153E-06	1.812E-03	(C) S768I
CA1	8q21.2	3 (0.42%)	4 (23.53%)		-5.81	6.76E-06	2.413E-03	(C) S768I
NRIP1	21q11.2-q21.1	3 (0.42%)	4 (23.53%)		-5.81	6.76E-06	2.413E-03	(C) S768I
TMPRSS11D	4q13.2	3 (0.42%)	4 (23.53%)		-5.81	6.76E-06	2.413E-03	(C) S768I
PPM1D	17q23.2	3 (0.51%)	4 (26.67%)		-5.70	8.603E-06	2.413E-03	(C) S768I
ASB10	7q36.1	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
BEST3	12q15	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
CEP44	4q34.1	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
CPT1A	11q13.3	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
ENTPD7	10q24.2	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I

EPDR1	7p14.1	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
FOXL1	16q24.1	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
GGNBP2	17q12	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
IFNLR1	1p36.11	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
KCNJ6	21q22.13	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
KRT3	12q13.13	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
MIOS	7p21.3	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
MOGAT2	11q13.5	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
OR6C2	12q13.2	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
PARVA	11p15.3	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
PPP2R5A	1q32.3	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
PSMD7	16q23.1	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
SIRPD	20p13	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
SKIV2L	6p21.33	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
WDR3	1p12	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
ZNF474	5q23.2	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
ZNF720	16p11.2	0 (0.00%)	3 (17.65%)		<-10	1.049E-05	2.413E-03	(C) S768I
ETNPPL	4q25	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
GPR34	Xp11.4	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
GTPBP1	22q13.1	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
PARP8	5q11.1	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
SLTM	15q22.1	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
SPOCD1	1p35.2	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
TEX11	Xq13.1	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
TMEM246	9q31.1	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
ZGPAT	20q13.33	4 (0.56%)	4 (23.53%)		-5.39	1.333E-05	2.635E-03	(C) S768I
ARHGAP10	4q31.23	5 (0.70%)	4 (23.53%)		-5.07	2.364E-05	4.4E-03	(C) S768I
CD5	11q12.2	5 (0.70%)	4 (23.53%)		-5.07	2.364E-05	4.4E-03	(C) S768I
CEP85L	6q22.31	5 (0.70%)	4 (23.53%)		-5.07	2.364E-05	4.4E-03	(C) S768I
MTHFD1	14q23.3	5 (0.70%)	4 (23.53%)		-5.07	2.364E-05	4.4E-03	(C) S768I
FLG	1q21.3	40 (5.60%)	7 (41.18%)		-2.88	3.463E-05	5.946E-03	(C) S768I
DNMT3A	2p23.3	6 (0.89%)	4 (25.00%)		-4.81	3.772E-05	5.946E-03	(C) S768I
ACOX3	4p16.1	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
DNAH6	2p11.2	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
GSTA1	6p12.2	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
KAT6B	10q22.2	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
NCOA7	6q22.31-q22.32	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
PLCB3	11q13.1	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
RNF6	13q12.13	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
SERPINA7	Xq22.3	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I

TUBGCP6	22q13.33	6 (0.84%)	4 (23.53%)		-4.81	3.884E-05	5.946E-03	(C) S768I
C6ORF136	6p21.33	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
CIZ1	9q34.11	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
DNA2	10q21.3	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
H6PD	1p36.22	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
LRIG1	3p14.1	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
LUZP4	Xq23	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
MTMR14	3p25.3	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
RAB3C	5q11.2	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
SYT3	19q13.33	1 (0.14%)	3 (17.65%)		-6.98	4.135E-05	5.946E-03	(C) S768I
FSHR	2p16.3	15 (2.10%)	5 (29.41%)		-3.81	4.536E-05	6.45E-03	(C) S768I
ADAM8	10q26.3	8 (1.12%)	4 (23.53%)		-4.39	8.895E-05	0.0122	(C) S768I
GPR52	1q25.1	8 (1.12%)	4 (23.53%)		-4.39	8.895E-05	0.0122	(C) S768I
MYO16	13q33.3	8 (1.12%)	4 (23.53%)		-4.39	8.895E-05	0.0122	(C) S768I
ANAPC7	12q24.11	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
CARD14	17q25.3	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
CH25H	10q23.31	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
FFAR1	19q13.12	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
GADD45A	1p31.3	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
MEIS3	19q13.32	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
OR2M7	1q44	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
TBC1D9B	5q35.3	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
TSNARE1	8q24.3	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
USP9X	Xp11.4	2 (0.28%)	3 (17.65%)		-5.98	1.019E-04	0.0126	(C) S768I
A2ML1	12p13.31	9 (1.26%)	4 (23.53%)		-4.22	1.266E-04	0.0151	(C) S768I
MCOLN3	1p22.3	9 (1.26%)	4 (23.53%)		-4.22	1.266E-04	0.0151	(C) S768I
PCDHA6	5q31.3	9 (1.26%)	4 (23.53%)		-4.22	1.266E-04	0.0151	(C) S768I
RAG1	11p12	9 (1.26%)	4 (23.53%)		-4.22	1.266E-04	0.0151	(C) S768I
NAALAD2	11q14.3	10 (1.40%)	4 (23.53%)		-4.07	1.747E-04	0.0201	(C) S768I
NME8	7p14.1	10 (1.40%)	4 (23.53%)		-4.07	1.747E-04	0.0201	(C) S768I
PKD1	16p13.3	10 (1.40%)	4 (23.53%)		-4.07	1.747E-04	0.0201	(C) S768I
TEX10	9q31.1	10 (1.40%)	4 (23.53%)		-4.07	1.747E-04	0.0201	(C) S768I
C11ORF88	11q23.1	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
CASZ1	1p36.22	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
DMWD	19q13.32	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
DPYSL4	10q26.3	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
GABRG3	15q12	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
GALNT15	3p25.1	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
GZMA	5q11.2	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
LDHA	11p15.1	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I

OPRL1	20q13.33	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
PCSK6	15q26.3	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
SMC1B	22q13.31	3 (0.42%)	3 (17.65%)		-5.39	2.008E-04	0.0210	(C) S768I
CDK17	12q23.1	2 (0.52%)	3 (25.00%)		-5.59	2.053E-04	0.0213	(C) S768I
FGF4	11q13.3	3 (0.43%)	3 (17.65%)		-5.37	2.109E-04	0.0217	(C) S768I
ADGRL1	19p13.12	11 (1.54%)	4 (23.53%)		-3.93	2.349E-04	0.0238	(C) S768I
MED13	17q23.2	11 (1.54%)	4 (23.53%)		-3.93	2.349E-04	0.0238	(C) S768I
MUC17	7q22.1	56 (7.84%)	7 (41.18%)		-2.39	2.483E-04	0.0249	(C) S768I
ITGA8	10p13	24 (3.36%)	5 (29.41%)		-3.13	3.061E-04	0.0305	(C) S768I
UHRF1BP1L	12q23.1	12 (1.68%)	4 (23.53%)		-3.81	3.086E-04	0.0305	(C) S768I
ADGRF2	6p12.3	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
AKR7A3	1p36.13	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
CEP89	19q13.11	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
COL23A1	5q35.3	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
CSF2RB	22q12.3	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
ELP4	11p13	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
MMEL1	1p36.32	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
NKTR	3p22.1	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
OR2M4	1q44	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
PARM1	4q13.3	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
TNNT3	11p15.5	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
VGLL1	Xq26.3	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
ZNF226	19q13.31	4 (0.56%)	3 (17.65%)		-4.98	3.464E-04	0.0311	(C) S768I
ABCB4	7q21.12	13 (1.82%)	4 (23.53%)		-3.69	3.978E-04	0.0355	(C) S768I
ACE	17q23.3	14 (1.96%)	4 (23.53%)		-3.58	5.041E-04	0.0398	(C) S768I
DSG2	18q12.1	14 (1.96%)	4 (23.53%)		-3.58	5.041E-04	0.0398	(C) S768I
TTC14	3q26.33	14 (1.96%)	4 (23.53%)		-3.58	5.041E-04	0.0398	(C) S768I
C7ORF31	7p15.3	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
CC2D2A	4p15.32	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
EHD2	19q13.33	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
EYA1	8q13.3	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
FAM193B	5q35.3	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
FIBP	11q13.1	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
GYG2	Xp22.33	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
HYKK	15q25.1	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
KLK13	19q13.41	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
LMAN2L	2q11.2	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
OR5AN1	11q12.1	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
SPANXN3	Xq27.3	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
TMEM161A	19p13.11	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I

TRMT1	19p13.13	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
TSPAN31	12q14.1	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
TUBA3D	2q21.1	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
ZNF829	19q13.12	0 (0.00%)	2 (11.76%)		<-10	5.097E-04	0.0398	(C) S768I
ADAM2	8p11.22	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
CPA4	7q32.2	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
CTTNBP2	7q31.31	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
DUSP19	2q32.1	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
ELL2	5q15	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
GPR141	7p14.1	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
ITGB4	17q25.1	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
KCTD19	16q22.1	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
SNX13	7p21.1	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
TSGA10	2q11.2	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
TULP1	6p21.31	5 (0.70%)	3 (17.65%)		-4.66	5.462E-04	0.0400	(C) S768I
GLI2	2q14.2	15 (2.10%)	4 (23.53%)		-3.49	6.293E-04	0.0455	(C) S768I
GRM1	6q24.3	15 (2.10%)	4 (23.53%)		-3.49	6.293E-04	0.0455	(C) S768I